Buspirone/testosterone (tentative brand name Lybridos) is a combination of buspirone, a 5-HT 1A receptor partial agonist, α 2-adrenergic receptor antagonist, and D 2 autoreceptor antagonist, and  testosterone, an androgen or androgen receptor agonist, which is under development by the pharmaceutical company Emotional Brain for the treatment of female sexual dysfunction.  Both buspirone and testosterone have individually been found to be effective in the treatment of female sexual dysfunction in clinical studies, and so their combination could be anticipated to be even more effective.    As of January 2016, the combination is in  phase II clinical trials, with a phase III trial being planned in the United States and Europe.
See also [ edit ]
References [ edit ]
Loane C, Politis M (2012). "Buspirone: what is it all about?". Brain Res. 1461: 111–8. doi: 10.1016/j.brainres.2012.04.032. PMID 22608068.
^ a b
"Buspirone/Testosterone - Emotional Brain - AdisInsight".
Meston, Cindy M.; Stanton, Amelia M. (2017). "Treatment of Female Sexual Interest/Arousal Disorder". The Textbook of Clinical Sexual Medicine. pp. 165–168. doi: 10.1007/978-3-319-52539-6_11. ISBN . 978-3-319-52538-9
Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R (2017). "Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review". Mayo Clin. Proc. 92 (1): 114–128. doi: 10.1016/j.mayocp.2016.09.018. PMID 27916394.
Nappi RE, Cucinella L (2015). "Advances in pharmacotherapy for treating female sexual dysfunction". Expert Opin Pharmacother. 16 (6): 875–87. doi: 10.1517/14656566.2015.1020791. PMID 25732267.
Bolour SY, Braunstein GD (2005). "Pharmacologic treatment options for hypoactive sexual desire disorder". Womens Health (Lond). 1 (2): 263–77. doi: 10.2217/17455057.1.2.263. PMID 19803843.
External links [ edit ]